34 results about "Premature thelarche" patented technology

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, and children for improving gastrointestinal function and tolerance, as well as the growth of beneficial bacteria. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.

The present invention relates to a commercially sterile liquid nutritional supplement for human milk for feeding infants such as premature or “failure to thrive” infants. The supplement is highly concentrated in order to produce a supplemented human milk that meets the nutritional needs of premature or “failure to thrive” infants in a volume that is well tolerated by the infants. The present invention relates also to methods to support the rapid growth of premature or “failure to thrive” infants by administering the nutritional supplement described herein to such infants.

The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, children, and adults for preventing injury and/or improving the healing of the gastrointestinal tract. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.

Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component.

A method for determining the effect of critical glyconutrient dietary supplements in premature and term infants on growth, health, and brain function during early childhood development is described. The method comprises determining a critical target nutrient profile in typical samples of preterm and mother's milk, developing a supplement of the missing critical target nutrients to simulate mother's milk, performing an evaluation of early child development by correlating physiologic brain function with cognitive/behavioral brain function in low birth weight premature and term infants, assessing family influence and home environment on developmental outcome on infants under treatment, and comparing term siblings of low birth weight premature vs. term babies. A composition having the critical nutrients, an algorithm for screening and treatment, and a useful kit for employing the above are also described.

Disclosed are nutritional compositions including galactooligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, children, and adults for preventing injury and/or improving the healing of the gastrointestinal tract. Additional suitable methods of using the nutritional compositions including the galactooligosaccharides are also disclosed.

The present invention relates to compositions and methods for enhancing the growth of infants. Particularly, the present invention discloses the use of insulin for promoting the growth of low birth weight infants, including preterm infants and small for gestational age (SGA) infants over the expected rate.

The invention discloses an incubator for premature infants and an incubator monitoring system for premature infants. The incubator for premature infants comprises an incubator box body, a baby tray disposed in the incubator box body, a main controller, a recording module and a play module; the recording module and the play module are respectively connected with the main controller. The incubator for premature infants has the benefits that the recording module is convenient for recording sounds of mothers' of the premature infants, such as appeasing sounds, laugher voices, singing voices, amusing sounds and the like, the sounds can be played through the play module to realize an appeasing effect, and the psychological emotion of the premature infants is pacified effectively, so that the premature infants placed in the incubator box body lie meekly, relax physically and mentally, and grow joyfully and cheerfully. If any premature infant placed in the incubator is in an abnormal condition, a voice alarm will be output from the voice alarm, and the medical staff can know and handle in time, thereby saving the trouble for the medical staff to be on duty 24 hours a day to guard each premature infant in each incubator. Furthermore, the incubator for premature infants is good in use effect.

An automatic breastfeeding method of a premature infant comprises a preparation stage, an active lactation stage, a passive lactation stage and a rest stage; the invention also provides an automatic breastfeeding machine used for the automatic breastfeeding method of premature infant, comprising a stomach tube, a lactation supply device, a detector and a control device. One end of the stomach tubeis arranged in the stomach of the premature infant, and the other end is connected with the lactation supply device, the milk supply device is electrically connected with the control device, the control device is electrically connected with the detector, and the detector is arranged in the mouth of the premature infant. The self-sucking ability of the premature infant is trained, and the normal circulation of the mouth-pharyngeal-gastric-intestinal reflex of premature infants is realized, and the nutritional requirements of the premature infants are ensured taking into account the differencesof the premature infants, so that the premature infants have no difference in the care, diet, neurological development and growth and development with term infants in the future.

The invention provides a soaking lotion for treatment of developmental retardation in premature infants and a preparation method and an application method thereof, and belongs to the technical field of treatment of developmental retardation in premature infants. The soaking lotion for treatment of developmental retardation in premature infants includes an herbal medicinal composition and animal fat and other tissue combinations F. The animal fat and other tissue combinations include snake gall powder, red deer bone powder, hive powder, badger liver capsule oil and other animal fats. The herbalmedicinal composition includes the following raw materials (by weight): 1-20 parts of herba schizonepetae, 1-20 parts of divaricate saposhnikovia root, 1-20 parts of notopterygium root, 1-20 parts oflevisticum, 1-20 parts of Radix Peucedani, 1-20 parts of balloonflower root, 1-20 parts of light red tuckahoe, 1-20 parts of ligusticum chuanxiong hort, 1-20 parts of licorice, 1-20 parts of cicada slough, 1-20 parts of arctium fruit, and 1-20 parts of Artemisia capillaries. By the bubble bath mode for treating developmental retardation in premature infants and with the combination of nutritionalsupport, growth parameters of child patients can reach normal values in a short time.

The usage of compounds that improve fetal and neonatal outcome of preterm birth is described. These compounds are scavengers of ROS, their precursors, and agents that induce production of the scavengers. Examples of these compounds are glutathione, NAC, antioxidants, and spin trapping compounds. These compounds improve fetal outcome by inhibiting a fetal inflammatory process that may affect the fetus independently of prematurity. This fetal inflammatory response is characterized by increased cytokine and matrix metalloproteases (MMP) levels both in the mother and fetus and may be modulated by ROS at different levels. Targeting ROS formation with compounds such as specific antioxidants, glutathione or spin trapping compounds, their precursors, and/or agents which induce their production will suppress both the direct effects of ROS and its indirect effects through cytokines and MMPs already circulating in the system. This therapeutical intervention would limit the pathophysiologoical chain of events that ultimately leads to PPROM, preterm birth and/or adverse fetal and neonatal outcome.

Disclosed is a composition for the prophylaxis or therapy of intraventricular hemorrhage in preterm infants comprising mensenchymal stem cells. Functioning to prevent ventricular dilatation and reduce the level of inflammatory cytokines in cerebrospinal fluid, the composition comprising mesenchymal stem cells is advantageously useful for the prophylaxis or therapy of intraventricular hemorrhage in preterm infants. Accordingly, the composition is effectively preventive of hydrocephalus which occurs subsequent to intraventricular hemorrhage. In addition, the composition makes not only a histological and biochemical recuperation in the intraventricular hemorrhage-injured brain, but also significantly improves sensory motor functions. Mesenchymal stem cells can be used as an effective therapeutic agent because they are less prone to induce immune rejection responses and are highly likely to secrete proliferative, differentiative, and regulatory factors. Hence, mesenchymal stem cells are expected to play a critical role in the therapy of intraventricular hemorrhage in preterm infants.

Disclosed is a method of identifying a greater risk for developing bronchopulmonary dysplasia (BPD) in a preterm infant. The method comprises obtaining a genomic DNA sample from the preterm infant's mother, identifying the nucleotide of rs2280789 SNP in the RANTES gene and the nucleotide of rs1800566 SNP in the NQO1 gene, and determining the preterm infant as being at risk of developing BPD when the genotype of rs2280789 SNP carries C nucleotide and the genotype of rs1800566 SNP carries T nucleotide.

The present invention relates to the use of nutritional compositions enriched in glutamine to improve structural and functional brain development in preterm and/or low birth weight infants.

Disclosed herein is a method for administering systemic (e.g., by intravenous injection) supplemental vascular endothelial growth factor (VEGF) to premature infants to prevent the disease sequelae and complications including but not limited to retinopathy of prematurity (ROP) and/or paraventricular leukomalacia (PVL) and/or bronchopulmonary dysplasia (BPD) associated with premature births. The VEGF is administered to the premature infant to produce a physiologic serum VEGF level that is substantially similar to the VEGF level found in a normally developing fetus in the utero. By way of one example, the retinal blood vessel growth of the premature infant is monitored, and the administration of VEGF is terminated when the infant's retinal blood vessels are substantially fully grown to ROP Zone 3. By virtue of the method herein disclosed, normal vessel growth occurs, and lung disease, ROP with blindness, brain damage and other diseases associated with premature birth are substantially avoided.